Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alumis Inc.

4.25
-0.0626-1.45%
Volume:87.18K
Turnover:370.27K
Market Cap:231.09M
PE:-0.41
High:4.49
Open:4.28
Low:4.16
Close:4.31
Loading ...

Alumis price target lowered to $14 from $15 at H.C. Wainwright

TIPRANKS
·
22 Apr

BRIEF-Alumis And Acelyrin Announce Amended Merger Agreement

Reuters
·
21 Apr

Alumis Raises Share Consideration for Acelyrin Acquisition

MT Newswires Live
·
21 Apr

ACELYRIN, INC. Amends Merger Agreement with Alumis

TIPRANKS
·
21 Apr

Alumis Inc - Expects Runway to Fund Operations Into 2027

THOMSON REUTERS
·
21 Apr

Alumis and ACELYRIN Announce Amended Merger Agreement

THOMSON REUTERS
·
21 Apr

Alumis Inc - ACELYRIN Stockholders to Receive 0.4814 Shares of Alumis per Share

THOMSON REUTERS
·
21 Apr

Press Release: Alumis and ACELYRIN Announce Amended Merger Agreement

Dow Jones
·
21 Apr

new option listings on April 9th

TIPRANKS
·
09 Apr

Alumis Down Over 31%, on Track for Record Percent Decrease -- Data Talk

Dow Jones
·
09 Apr

Alumis Reaches US$465m Market Cap Benefiting Insider Stock Buying

Simply Wall St.
·
05 Apr

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

THOMSON REUTERS
·
05 Apr

Alumis Inc. Reports 2024 Results and Strategic Merger

TIPRANKS
·
27 Mar

Alumis Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Mar

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live
·
26 Mar

BUZZ-Alumis jumps on licensing deal for skin drug

Reuters
·
25 Mar

Alumis Shares Rise on Licensing Agreement with Japanese Drug Company

Dow Jones
·
25 Mar

Alumis Shares up 26.5% After Licensing Agreement With Kaken Pharmaceutical

THOMSON REUTERS
·
25 Mar

Alumis Shares Jump 67.4% Premarket After Licensing Agreement With Kaken Pharmaceutical

THOMSON REUTERS
·
25 Mar

Alumis, Kaken Pharmaceutical Enter Collaboration, Licensing Deal for Dermatology Drug

MT Newswires Live
·
25 Mar